- CCG-203971
-
- $48.00
-
2026-07-27
- CAS:1443437-74-8
- Purity: 99.50%
- Supply Ability: 10g
|
| | CCG-203971 Basic information |
| Product Name: | CCG-203971 | | Synonyms: | CCG-203971;CCG 203971;CCG203971;CCG-203971;N-(4-Chlorophenyl)-1-[3-(2-furanyl)benzoyl]-3-piperidinecarboxamide;N-(4-chlorophenyl)-1-[3-(furan-2-yl)benzoyl]piperidine-3-carboxamide;203971;3-Piperidinecarboxamide, N-(4-chlorophenyl)-1-[3-(2-furanyl)benzoyl]-;Rho,Ras,Inhibitor,SRF,CCG 203971,CCG-203971,MKL1,inhibit,MRTF,anti-metastasis,PC-3,migration;CC 203971 | | CAS: | 1443437-74-8 | | MF: | C23H21ClN2O3 | | MW: | 408.88 | | EINECS: | | | Product Categories: | | | Mol File: | 1443437-74-8.mol |  |
| | CCG-203971 Chemical Properties |
| Boiling point | 656.0±55.0 °C(Predicted) | | density | 1.305±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO:81.0(Max Conc. mg/mL);198.1(Max Conc. mM) | | form | powder | | pka | 13.69±0.70(Predicted) | | color | white to beige | | InChI | 1S/C23H21ClN2O3/c24-19-8-10-20(11-9-19)25-22(27)18-6-2-12-26(15-18)23(28)17-5-1-4-16(14-17)21-7-3-13-29-21/h1,3-5,7-11,13-14,18H,2,6,12,15H2,(H,25,27) | | InChIKey | HERLZBNILRVHQN-UHFFFAOYSA-N | | SMILES | ClC(C=C1)=CC=C1NC(C(C2)CCCN2C(C3=CC(C4=CC=CO4)=CC=C3)=O)=O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | CCG-203971 Usage And Synthesis |
| Uses | CCG 203971 acts as an antifibrotic agent, inhibiting fibrosis through targeting the MRTF/SRF gene transcription pathway. Inhibits the invasion of prostate cancer cells and acts as a potent anti-proliferative agent. | | Biochem/physiol Actions | CCG-203971 is an inhibitor of the Rho/MKL1/SRF transcriptional pathway, which has been shown to play a role in metastasis of melanoma and breast cancer and clinically associated with castration-resistant prostate cancer. CCG-203971 is a second-generation analog of CCG-1423 (SML0987) with an IC50 of 4.2 μM vs 1 μM for CCG-1423, but less cytotoxicity. In mouse studies, CCG-203971 inhibited invasion of PC-3 prostate cancer cells and was well tolerated up to doses of 100 mg/kg IP over 5 days. The Rho/MRTF/SRF pathway has also been shown to be involved in multiple types of solid organ fibrosis. CCG-203971 repressed both matrix-stiffness and TGF-β-mediated fibrogenesis in human colonic myofibroblasts and showed antifibrotic activity in a murine model of skin injury and in pulmonary fibrosis lung fibroblasts. | | in vivo | CCG-203971 is tested in a Bleomycin skin injury model. Bleomycin is administered in 50 μL of DMSO intraperitoneally. Preliminary studies show that Bleomycin administered in this manner is well tolerated at 100 mg/kg twice a day. Intradermal Bleomycin for 2 weeks along with the DMSO control (50 μL i.p.) results in marked dermal thickening (P<0.0001) compared with the PBS+DMSO group, which does not receive Bleomycin. CCG-203971 treatment strongly and significantly (P<0.001) suppresses the Bleomycin-induced skin thickening in this model. Skin collagen amounts, assessed by measurement of hydroxyproline content, show similar results. Bleomycin injections promote collagen deposition (P<0.01) and CCG-203971 is able to block this effect (P<0.05)[3]. |
| | CCG-203971 Preparation Products And Raw materials |
|